

PTO/SB/82 (01-02)

Approved for use through 12/31/2008. OMB 0851-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/680,087
	Filing Date	10/06/2003
	First Named Inventor	Norbert Lamping
	Art Unit	1649
	Examiner Name	Borgeest, Christina M.
	Attorney Docket Number	040025U007

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 43,309

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number: 43,309

OR

☐ Firm or Individual Name

Address

City State Zip

Country


Telephone Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature 

Name DAVID T. GIDDINGS

Date 5/11/07 Telephone 612-864-3864

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-6199 and select option 2.

PTO/SB/96 (09-06)

Approved for use through 03/31/2007, OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Digilab BioVision GmbHApplication No./Patent No.: 10/689,087 Filed/Issue Date: October 6, 2003Entitled: METHOD FOR DETECTING CHRONIC DEMENTIA DISEASES, AND CORRESPONDING VGF PEPTIDES AND DETECTION REAGENTSDigilab BioVision GmbH

(Name of Assignee)

a corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 015086, Frame 0348, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Printed or Typed Name

Title

Date

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-5199 and select option 2.

ASSIGNMENT

WHEREAS, BioVision AG, a corporation located at Feodor-Lynen-Strasse 5, Hannover, Germany, D-30625 (hereinafter "ASSIGNOR") is the owner of the inventions listed on attached Schedule A (hereinafter "Inventions").

WHEREAS, it is the intention of ASSIGNOR, and Digilab BioVision GmbH, a corporation having a place of business at Feodor-Lynen-Strasse 5, Hannover, Germany, D-30625 (hereinafter "ASSIGNEE"), that ASSIGNEE own all of ASSIGNOR's right, title and interest in and to the Inventions, including all of ASSIGNOR's U.S., foreign and international patent rights therein;

NOW, THEREFORE, pursuant to this Assignment, ASSIGNOR hereby distributes, assigns, conveys and transfers to ASSIGNEE, its successors and assigns, all of ASSIGNOR's right, title and interest in and to the Inventions, including all patent applications, and to the inventions therein disclosed and claimed and to all international priority rights relating thereto throughout the world, and in and to any continuations, divisions, reissues, reexaminations and extensions thereof, along with any and all rights of enforcement with respect thereto, including all rights to sue and/or recover for the past, present and future infringement thereof, and any and all causes of action related thereto. ASSIGNEE may apply for and receive patents in its own name wherever so permitted by law.

ASSIGNOR shall, when requested by ASSIGNEE, execute all rightful oaths, assignments, and powers of attorney, including but not limited to the right to file and prosecute in its own name, wherever so permitted by law, patent applications, including corresponding applications outside of the U.S., and to claim priority of patent applications pursuant to the Paris Convention, to ASSIGNEE and to agents and legal representatives of ASSIGNEE, and all other papers necessary and proper to carry out the intent and purpose of this Invention Assignment.

IN WITNESS WHEREOF, ASSIGNOR has executed this Assignment on this 25 day of April, 2007.

BioVision AG

By: [Signature]

Print Name: WACHSMUTH, HELGE

Title: Managing Administrator of BioVision AG

Witnessed by: [Signature]

Print Name: MÖRS, URSULA

1. U.S. Patent Application No. 10/549,141 filed July 3, 2006, with an international filing date of March 18, 2004. BIOVISION AG is owner of patent application pursuant to Assignment recorded at the United States Patent and Trademark Office at Reel/Frame No. 017964/0615, under the title "METHOD FOR DETECTING A PROGRESSIVE, CHRONIC DEMENTIA DISEASE, AND CORRESPONDING PEPTIDES AND DETECTION REAGENTS"
2. U.S. Patent Application No. 10/497,073 filed on October 26, 2004 BIOVISION AG is owner of patent application pursuant to Assignment recorded at the United States Patent and Trademark Office at Reel/Frame No. 015925/0599, under the title "METHOD FOR DETECTING ALZHEIMER'S DISEASE AND DIFFERENTIATING ALZHEIMER'S DISEASE FROM OTHER DEMENTIAL DISEASES, ASSOCIATED PEPTIDES AND THE USE THEREFOR"
3. U.S. Patent Application No. 10/680,087 filed on October 6, 2003. BIOVISION AG is owner of patent application pursuant to Assignment recorded at the United States Patent and Trademark Office at Reel/Frame No. 015086/0348, under the title "METHOD FOR DETECTING CHRONIC DEMENTIA DISEASES, AND CORRESPONDING VGF PEPTIDES AND DETECTION REAGENTS."